Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsFRA:MYD -5.65%58 EV-to-FCF is -52.98 as of Jul. 31, 2026. GuruFocus rates FRA:MYD with a GF Score™ of 58/100 and a GF Value™ of €12.24 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 999999% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Myriad Genetics's Enterprise Value is €518.3 Mil.
Myriad Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-9.8 Mil. Therefore, Myriad Genetics's EV-to-FCF for today is -52.98.
The historical rank and industry rank for Myriad Genetics's EV-to-FCF or its related term are showing as below:
FRA:MYD'
s EV-to-FCF Range Over the Past 10 Years
Min: -325.04 Med: -9.85 Max: 3299.13
Current: -25.62
During the past 13 years, the highest EV-to-FCF of Myriad Genetics was 3299.13. The lowest was -325.04. And the median was -9.85.
FRA:MYD's EV-to-FCF is ranked worse than 100% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.53
vs FRA:MYD: -25.62
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Myriad Genetics's PE Ratio (TTM) for today is calculated as:
Myriad Genetics's share price for today is €4.325.
Myriad Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.025.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Myriad Genetics EV-to-FCF Related Terms
Myriad Genetics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Myriad Genetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's EV-to-FCF falls into.
Myriad Genetics's current Enterprise Value is €518.3 Mil.
Myriad Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (FRA:MYD) has a EV-to-FCF of -52.98 as of Jul. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry.
Is Myriad Genetics' EV-to-FCF too high?
Myriad Genetics' current EV-to-FCF is -52.98. Based on the distribution chart, Myriad Genetics ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' EV-to-FCF compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #999999 out of 100 companies for EV-to-FCF. This places Myriad Genetics in the lower half of its industry. The industry median EV-to-FCF is 26.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.53, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current EV-to-FCF is -52.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €12.24, compared to a current price of €4.33 — trading 64.7% below its estimated fair value. The current EV-to-FCF is -52.98. Myriad Genetics' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current EV-to-FCF is -52.98 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (FRA:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.33 is trading 64.7% below its estimated GF Value™ of €12.24.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for FRA:MYD:
EV-to-FCF: -52.98
GF Value™: €12.24 vs. price of €4.33 (64.7% below fair value)
No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
58GF Score
Get the complete analysis for FRA:MYD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MYD has been successfully added to your 
